Many patients with cancer take antioxidant nutritional supplements during cancer treatment to alleviate treatment toxicities and to improve long-term outcomes, but little is known about the efficacy and safety of antioxidant use during cancer treatment. We reviewed English-language manuscripts published in the biomedical literature, reporting the results of observational studies of antioxidant status and cancer outcomes and of intervention trials of antioxidants among patients receiving chemotherapy with or without radiation for various malignancies.
INTRODUCTION
Recent surveys of patients with cancer have demonstrated that many (25% to 84%) use nutritional supplements containing antioxidants, often at doses higher than the recommended dietary allowances [1] [2] [3] . Patients with cancer take antioxidant supplements during or after conventional cancer treatment to enhance the benefits of treatment, to alleviate side effects, and/or to maintain or improve general health and well-being. However, the evidence that any antioxidant supplement has efficacy for any of those purposes is sparse and largely indirect.
In vitro and in vivo data suggest that certain antioxidants selectively inhibit the growth of tumor cells, may induce cellular differentiation, and may alter the intracellular redox state, thereby enhancing the effects of cytotoxic therapy [4] [5] [6] [7] [8] . Some investigators have argued that average concentrations of antioxidants may not be sufficient to counter the higher production of reactive oxygen metabolites, and may therefore promote cell proliferation and malignant progression [9] . Moreover, the suggestion of an association between beta carotene intake and increased risk of lung cancer in two lung cancer chemoprevention trials has generated concern about the cancer promoting effects of antioxidants [10, 11] . Antioxidants may also reduce certain types of toxicity associated with chemotherapy, but it is feared that they may do so by interfering with the efficacy of conventional therapy [12, 13] .
A rationale for antioxidant supplementation during chemotherapy is to compensate for treatment-or cancerinduced antioxidant depletion. The evidence for such depletion is limited. Some studies have explored the effect of conventional therapy on antioxidant status (as measured by serum micronutrients and/or total antioxidant capacity) in patients with cancer diagnoses. Others have explored the effects of supplementation of individual antioxidants or combinations of antioxidant supplements with chemotherapy in a variety of patient populations. Yet, no cohesive review of these results has been published.
To learn about the relationship between antioxidants and chemotherapy, we conducted a systematic review of the published trials and observational studies investigating: (1) The effects of conventional chemotherapy with or without radiation on antioxidant status; (2) the effects of antioxidant status on treatment-related toxicities and event-free survival; (3) the effects of antioxidant supplementation in combination with conventional chemotherapy with or without radiation on antioxidant status; and (4) the effects of antioxidant supplementation on treatment-related toxicities and event-free survival.
METHODS
Epidemiologic and clinical studies included in this review were identified through repeated literature searches conducted from July 2000 to January 2002. The MEDLINE and Cochrane database was searched for published manuscripts. The reference terms "antioxidants," "supplements," "vitamins," "diet," "nutrition," "cancer," "chemotherapy," "chemotherapy toxicity," and "cancer survival" were used as both keyword and subject terms. In the MEDLINE database, the search was limited to human studies published in English. In addition, journal manuscripts cited in the primary-search manuscripts were collected and added to the review. Data were extracted from the manuscripts using a standardized methodology [14, 15] . We included only studies that investigated antioxidant levels and/or antioxidant supplementation in patients receiving chemotherapy with or without radiation therapy for cancer. Studies investigating antioxidant levels in patients with cancer at diagnosis only, after cancer therapy, receiving only radiation therapy, or not receiving cancer therapy, were excluded. Studies investigating other nutrients (nutritional supplements, herbal preparations) with antioxidant capacity, but not defined in the dietary reference intakes as being required from the diet were not included in this review. Studies that reported assessment of vitamins C, E, selenium, or ␤-carotene as either the primary or a secondary aim were included. Table 1 describes 31 observational studies reporting changes in serum, plasma, or whole blood levels of vitamins C and E, selenium, ␤-carotene, and total radical antioxidant parameter (TRAP), which represents total body antioxidant status, in patients undergoing anticancer therapy. Information is grouped by malignancy and includes subject demographics, cancer data, cancer treatment, end points evaluated, results, and comments. No specific treatment was consistently associated with changes in the individual antioxidants (Table 1) .
RESULTS

Observational Studies
Three studies reported that TRAP levels decreased after chemotherapy [16] [17] [18] . However, the sample sizes in all three studies were small (39, 24, and 12 patients, respectively). In two of the studies, the patients were undergoing high-dose chemotherapy before bone-marrow transplant [16, 17] ; in the third study, the patients were undergoing therapy for lung cancer [18] .
Hematologic malignancies. Twelve observational studies (nine case-control and three cohort) reported on antioxidant status in patients with hematologic malignancies; sample sizes ranged from 13 to 269 subjects. Only eight studies described the anticancer agents administered to patients, and the eight protocols varied. Three studies suggested that after initiation of treatment, vitamin C levels may increase [16, 17, 19] ; one found that plasma ascorbic acid concentrations decreased [20] , and one reported that plasma ascorbic acid decreased while dehydroascorbic acid increased [21] . Six studies reported low vitamin E levels in patients receiving high-dose chemotherapy before a bone marrow transplant [16, 17, [22] [23] [24] [25] , but the largest study (n ϭ 269) found no change in vitamin E [25] . However, the treatments and the timing of blood sampling in relation to treatment varied. This was also observed in studies assessing ␤-carotene and selenium levels [22] [23] [24] [26] [27] [28] .
Breast cancer. Four studies investigated antioxidant status in patients with breast cancer undergoing cancer therapy. Potischman et al [29] suggested that vitamin E, as measured by ␣-tocopherol and ␥-tocopherol, increased with the initiation of chemotherapy, but this finding coincided with an increase in energy intake; however, another study found the opposite [30] . A third study reported that vitamin E levels increased with the initiation of tamoxifen [31] , whereas a fourth study found no significant changes [32] .
Lung, gynecologic, and testicular cancer. Five studies investigated subjects with lung [18], gynecologic [33, 34] , and testicular cancers [35, 36] . Different end points, therapies, stages of malignancy, and timing of blood withdrawal preclude any systematic comparisons.
Heterogeneous cancers. Ten observational studies investigated antioxidant status in subjects with a range of malignancies (both hematologic and solid) and compared subjects treated on varying protocols and with different classes of anticancer agents [33, [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] . Sample sizes varied (range, N ϭ 14 to N ϭ 802), and the timing of blood withdrawal ranged from diagnosis to hours, days, or months after initiation of treatment. No trends among these studies were observed. 
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Clinical Trials
Effects of supplementation on blood antioxidant levels. Table 2 describes nine trials in which the effects of various supplements on plasma, serum, and/or platelet antioxidant levels were assessed. These studies are grouped by malignancy and describe subjects, diagnosis, cancer therapy, dosage and mode of antioxidant supplementation, end points evaluated, results, and comments.
Hematologic malignancies. Five studies were performed in patients with hematologic malignancies [22, [47] [48] [49] [50] . In the four studies that included oral or intravenous vitamin C alone or in combination with other vitamins, no clear trends emerged [47] [48] [49] [50] . Only one study investigated the independent effect of vitamin C [50]. Patients with acute leukemia or chronic myelogenous leukemia who received vitamin C supplements had significant increases in platelet and plasma levels of vitamin C (P Ͻ .025, P Ͻ .025, respectively); patients with chronic lymphocytic leukemia experienced a significant increase in plasma vitamin C levels (P Ͻ .05).
Three of the five studies in patients with hematologic malignancies investigated the effects of vitamin E supplementation in combination with other nutrients on plasma vitamin E, ␣-tocopherol/RBC membranes ratio, ␣-tocopherol/cholesterol ratio, or serum vitamin E [22,47,48]. Abbreviations: y, years; HD, Hodgkin's disease; Chemotx, chemotherapy; TBI, total body irradiation; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin's lymphoma; PV, polycythemia vera; CML, chromic myelocytic leukemia; MM, multiple myeloma; AL, acute leukemia; MDS, myelodysplastic syndrome; CGL, chronic granulocytic leukemia; NB, neuroblastoma; SAA, severa aplastic anemia; BU, busulfan; VP 6, etoposide; CY, cyclophosphamide; NR, not reported; PRED, prednisone; VCR, vincristine; 6-MP, 6-mercaptopurine; END, endoxane; ADR, adriamycin; MELPH, melphalan; TRAP, total radical antioxidant parameter; VC, vitamin C; ␣-Toc, alpha tocopherol; ␥-Toc, gamma tocopherol; VE, vitamin E; AsA, ascorbate; ASR, ascorbyl radical; AA, ascorbic acid; DasA, dehydroascorbic acid; Chol, cholesterol; ␤-Car, beta carotene; ANLL, acute non-lymphocytic leukemia; CLL, chronic lymphocytic leukemia; RT, radiation therapy; DNR, daunorubicin; CAR, cytarabine; DHAD, mitoxantrone; AMSA, amsacrine; Se, selenium; 2, decrease; 1, increase; dx, diagnosis; SCLC, small-cell lung cancer; TAM, tamoxifen; MTX, methotrexate; FU, fluorouracil; FTO, ftorafure; CIS, cisplatin; DXR, doxorubicin; CR, complete remission; Hist, histiocytosis; OS, osteosarcoma; RB, rhabdomyosarcoma; NB, neuroblastoma; H/N, head and neck cancer; GI, gastrointestinal cancer; GU, genitourinary cancer; IFOS, ifosfamide; Dexa, dexamethasone; hr, hours.
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Among patients receiving intensive conditioning chemotherapy in the setting of bone marrow transplant (especially those receiving concomitant total-body irradiation), serum vitamin E levels decreased even among patients receiving the recommended dietary allowances of vitamins by total parenteral nutrition [22, 49] . Low-dose vitamin E (9 mg) supplementation through total parenteral nutrition did not prevent a decrease in one study [22] , and supplementation with 1,000 U of vitamin E combined with low-dose vitamin C (25 mg) had no effect on serum vitamin E or plasma vitamin C levels in another trial [48] . However, another study demonstrated that supplementation with ␣-tocopherol (825 mg), ␤-carotene (45 mg), and vitamin C (450 mg) by mouth prevented a decline in plasma antioxidant levels [47] .
Lung cancer. One nonrandomized trial was undertaken in patients with lung cancer [51] . Antioxidant supplementation (10,000 to 12,000 U ␤-carotene, 300 to 800 U ␣-tocopherol, 2,000 to 5,000 U ascorbic acid, 856 g selenium) resulted in no significant changes in plasma selenium or ␣-tocopherol.
Gynecologic malignancies. In two randomized trials [52,53] among patients with gynecologic cancers, patients were treated with doxorubicin, cyclophosphamide, cisplatin with ftorafure or melphalan, and the supplements: selenium (96 g or 200 g), vitamin E (300 mg), selenium and vitamin E, or placebo. Both studies reported significantly increased levels of serum selenium but not vitamin E after the initiation of supplementation.
Breast cancer. In a study evaluating patients with breast cancer [54] supplemented with selenium (387 g) in combination with vitamin C (2,850 mg), vitamin E (2,500 U), ␤-carotene (32,500 U), coenzyme Q-10, essential fatty acids, and other vitamin and minerals, increases in whole blood ␤-carotene (P Ͻ .01), vitamin E (P Ͻ .05), and selenium (P Ͻ .01) were observed 3 and 12 months after the start of supplementation.
Taken together, the intervention trials suggest a direct effect of selenium supplementation on serum or whole blood selenium concentrations, despite the variations in malignancies, regimens, and stages of cancer among the patients studied.
Effects of supplementation on chemotherapy-related toxicities. Table 3 describes the results of 12 trials investigating the effects of antioxidant supplementation on chemotherapy-related toxicities. Three studies specifically evaluated the effects of supplementation on common toxicities associated with chemotherapy including nausea/vomiting, fatigue, bone marrow suppression, and diarrhea [55-57]. In patients with ovarian cancer treated with cisplatin and cyclophosphamide, patients who received 3 months of selenium supplementation had significantly higher (P Ͻ .05) neutrophil counts (but not other hematologic indices) and less nausea/vomiting, abdominal pain, weakness, malaise, and anorexia than controls [55] . Selenium administration reduced cisplatin-induced nephrotoxicity in the acute stages (24 to 48 hours), but not over long-term (Ͼ 72 hours) [56] . A phase I trial of fluorouracil, leucovorin, and high-dose vitamin E (3,200 U) among nine patients with advanced disease showed no benefit (partial or complete response) and no reduction or increase in toxicity [57] .
Four trials investigated the effects of antioxidant supplementation (vitamin E alone or as part of a combination therapy) on cardiac toxicity in patients receiving anthracycline-based therapy [54-57]. One study found that vitamin E with nifedipine prevented a decrease in left ventricular ejection fraction, especially in the setting of adjuvant radiotherapy, and accelerated the distribution and elimination of doxorubicin (P Ͻ .05) [58] . The other studies found no effect [ 
DISCUSSION
Our review of the observational studies of the effects of chemotherapy on antioxidant levels supports the hypothesis that chemotherapy lowers total antioxidant status, but this was assessed in a limited number of studies [16] [17] [18] . Studies of changes in vitamins C and E, selenium, and ␤-carotene found no consistent patterns associated with chemotherapy [16-32,34-46,52]. Based on these studies, we can only conclude that the effect of chemotherapy on levels of the antioxidants assessed is not great enough to have overridden differences in study methodologies, patient populations, cancer organ or site, conventional chemotherapy treatment, and timing of data collection in relation to the natural history of the cancer and its treatment.
An explanation for the lack of consistent change in antioxidant status after chemotherapy treatment may be that patients were depleted of antioxidants before initiation of treatment, perhaps because cancer cells use antioxidant vitamins more efficiently than healthy cells, thus depleting circulating plasma levels of antioxidants. This hypothesis is supported by the studies that found that cancer patients had lower levels of antioxidants than controls, even before the initiation of treatment [9,13,38,44,45,67]. These observations suggest that low antioxidant status may be associated with neoplastic activity and subsequent poor health and support the idea that antioxidant supplementation could benefit cancer patients. The initiation of anticancer therapy may also lower levels of antioxidants by affecting dietary intake, but as treatment progresses and the cancer cell burden declines, antioxidant levels may improve. Different agents, in the setting of different cancers and stages may also vary in their effects on antioxidant levels [16,17,29,34,37]. However, the finding that TRAP (a measure of total antioxidant capacity) levels consistently decreased, while the individual antioxidants showed no consistent changes, suggests that factors other than known antioxidants may contribute to changes in the total antioxidant status of the body during chemotherapy.
The clinical trials suggest that individual antioxidants administered in conjunction with conventional therapy may affect serum values for some nutrients but not others. Selenium supplementation appears to have the most consistent effect on selenium levels in patients undergoing chemotherapy.
The antioxidant most publicized for its potential benefits to cancer patients is vitamin C. The intervention studies in this review supplemented patients with vitamin C orally or as part of total parental nutrition, but doses did not exceed 5,000 mg. None of the studies reported a beneficial effect from vitamin C [68,69]. Double-blind randomized control trials investigating a high-dose regimen failed to find a significant effect [68] .
Much of the debate surrounding antioxidants in combination with chemotherapy has centered on regimens that are believed to achieve their cytotoxic effects by generating free radicals, such as alkylating agents, antimetabolites and radiation. The mechanisms of these agents have been extensively reviewed [70] . In theory, antioxidants may decrease the efficacy of these agents by quenching free radicals. Lenzhofer et al [58] found that supplementation with vitamin E altered the metabolism of doxorubicin. However, such interactions may not necessarily reduce treatment efficacy; certain adjunctive agents, such as mesna, exert their effects through the quenching of free radicals and do not appear to decrease the efficacy of chemotherapy. Similarly, amifostine, an agent with antioxidant properties, is utilized to reduce the side effects associated with cisplatin therapy. Individuals treated with anticancer agents that deplete antioxidant status may require replenishment of antioxidants after treatment, just as patients receiving high-dose methotrexate require leucovorin rescue. Antioxidant supplements may reduce the frequency and severity of toxicity associated with anticancer therapy. Antioxidant use might make it possible to administer higher and more effective doses of chemotherapy.
However, the published studies reviewed here do not provide evidence that individual antioxidant vitamin supplements reduces the toxicity associated with anticancer Two of the studies reviewed suggested that supplementation with selenium might reduce the hematologic toxicity and nephrotoxicity associated with cisplatin-containing regimens [55, 56] . However, follow-up was not long enough for assessment of effects on survival. Moreover, various regimens were studied and the timing of the interventions were not reported clearly. None of the intervention studies reported controlling for dietary intake of antioxidants in a systematic manner, despite consistent findings that dietary intake of foods high in antioxidants alters serum levels [71] .
Prospective studies investigating the effects of antioxidant supplementation before diagnosis on breast cancer mortality suggest that high intake of vitamin C may be beneficial [72] [73] [74] [75] . Epidemiologic studies in patients with prostate cancer suggest that selenium and vitamin E may reduce the risk of prostate cancer [76] . This review found no effect of antioxidant supplementation during treatment on survival, but the six relevant studies differed in design and exposure and outcome measures. Studies of the effects of antioxidant supplementation on cancer recurrence and survival should specify both dosage and duration of supplementation and lifestyle (diet, exercise, and so on) in a defined population.
A major barrier to the determination of the effects of antioxidants is the variability of doses, timing, and duration of supplementation in the studies reviewed. The recommended dietary allowances (RDA) for vitamins and minerals are commonly applied to patients with cancer, but the RDA is intended to establish a guideline to prevent nutrient deficiencies and promote health in the majority of healthy individuals; they do not necessarily apply to individuals suffering from a chronic illness or individuals under metabolic stress [77] . The RDA may especially be insufficient to maintain plasma antioxidant levels in patients undergoing high-dose chemotherapy before stem-cell transplant.
Additional studies investigating the effects of antioxidants are needed. Ideally, they should be incorporated into large-scale phase III clinical trials in relatively homogeneous patient populations receiving well-specified conventional treatment regimens. These studies should control for behavioral factors, such as use of complementary/alternative medicine, patient compliance, and carcinogen exposure, particularly for those cancers strongly associated with a specific carcinogen such as lung cancer with tobacco use [29] . In such settings, the variability observed in our review of the literature would not obscure the true effect, if any, of antioxidant supplementation. 
